155 related articles for article (PubMed ID: 37285798)
21. Effect of alemtuzumab-based T-cell depletion on graft compositional change in vitro and immune reconstitution early after allogeneic stem cell transplantation.
Roex MCJ; Wijnands C; Veld SAJ; van Egmond E; Bogers L; Zwaginga JJ; Netelenbos T; von dem Borne PA; Veelken H; Halkes CJM; Falkenburg JHF; Jedema I
Cytotherapy; 2021 Jan; 23(1):46-56. PubMed ID: 32948458
[TBL] [Abstract][Full Text] [Related]
22. Impact of Treosulfan Exposure on Early and Long-Term Clinical Outcomes in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients: A Prospective Multicenter Study.
van der Stoep MYEC; Bertaina A; Moes DJAR; Algeri M; Bredius RGM; Smiers FJW; Berghuis D; Buddingh EP; Mohseny AB; Guchelaar HJ; Locatelli F; Zwaveling J; Lankester AC
Transplant Cell Ther; 2022 Feb; 28(2):99.e1-99.e7. PubMed ID: 34607071
[TBL] [Abstract][Full Text] [Related]
23. In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial.
Marks DI; Clifton-Hadley L; Copland M; Hussain J; Menne TF; McMillan A; Moorman AV; Morley N; Okasha D; Patel B; Patrick P; Potter MN; Rowntree CJ; Kirkwood AA; Fielding AK
Lancet Haematol; 2022 Apr; 9(4):e276-e288. PubMed ID: 35358442
[TBL] [Abstract][Full Text] [Related]
24. Alemtuzumab as graft-versus-host disease (GVHD) prophylaxis strategy in a developing country: lower rate of acute GVHD, increased risk of cytomegalovirus reactivation.
Resende CB; Rezende BM; Bernardes PT; Teixeira GM; Teixeira MM; Pinho V; Bittencourt H
Braz J Med Biol Res; 2017 Feb; 50(2):e5566. PubMed ID: 28198910
[TBL] [Abstract][Full Text] [Related]
25. High frequencies of CD62L⁺ naive regulatory T cells in allografts are associated with a low risk of acute graft-versus-host disease following unmanipulated allogeneic haematopoietic stem cell transplantation.
Lu SY; Liu KY; Liu DH; Xu LP; Huang XJ
Clin Exp Immunol; 2011 Aug; 165(2):264-77. PubMed ID: 21635226
[TBL] [Abstract][Full Text] [Related]
26. Donor-Host Lineage-Specific Chimerism Monitoring and Analysis in Pediatric Patients Following Allogeneic Stem Cell Transplantation: Influence of Pretransplantation Variables and Correlation with Post-Transplantation Outcomes.
Llaurador G; Nicoletti E; Prockop SE; Hsu S; Fuller K; Mauguen A; O'Reilly RJ; Boelens JJ; Boulad F
Transplant Cell Ther; 2021 Sep; 27(9):780.e1-780.e14. PubMed ID: 34082161
[TBL] [Abstract][Full Text] [Related]
27. Risk Factors, Clinical Outcomes, and Cost-of-Care Related to Graft Failure in Pediatric Allogeneic Hematopoietic Cell Transplant Recipients.
Wobma H; Jin Z; Moscoso S; Bhatia M; Broglie L; George D; Garvin J; Satwani P
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1318-1325. PubMed ID: 32194288
[TBL] [Abstract][Full Text] [Related]
28. Natural History of Epstein-Barr Virus Replication and Viral Load Dynamics after Alemtuzumab-Based Allogeneic Stem Cell Transplantation.
Marzolini MAV; Wilson AJ; Sanchez E; Carpenter B; Chakraverty R; Hough R; Kottaridis P; Morris EC; Thomson KJ; Peggs KS
Transplant Cell Ther; 2021 Aug; 27(8):682.e1-682.e12. PubMed ID: 33962069
[TBL] [Abstract][Full Text] [Related]
29. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study.
Güngör T; Teira P; Slatter M; Stussi G; Stepensky P; Moshous D; Vermont C; Ahmad I; Shaw PJ; Telles da Cunha JM; Schlegel PG; Hough R; Fasth A; Kentouche K; Gruhn B; Fernandes JF; Lachance S; Bredius R; Resnick IB; Belohradsky BH; Gennery A; Fischer A; Gaspar HB; Schanz U; Seger R; Rentsch K; Veys P; Haddad E; Albert MH; Hassan M;
Lancet; 2014 Feb; 383(9915):436-48. PubMed ID: 24161820
[TBL] [Abstract][Full Text] [Related]
30. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia.
Marsh JC; Gupta V; Lim Z; Ho AY; Ireland RM; Hayden J; Potter V; Koh MB; Islam MS; Russell N; Marks DI; Mufti GJ; Pagliuca A
Blood; 2011 Aug; 118(8):2351-7. PubMed ID: 21518925
[TBL] [Abstract][Full Text] [Related]
31. Early cytomegalovirus reactivation leaves a specific and dynamic imprint on the reconstituting T cell compartment long-term after hematopoietic stem cell transplantation.
Lugthart G; van Ostaijen-Ten Dam MM; Jol-van der Zijde CM; van Holten TC; Kester MG; Heemskerk MH; Bredius RG; van Tol MJ; Lankester AC
Biol Blood Marrow Transplant; 2014 May; 20(5):655-61. PubMed ID: 24462981
[TBL] [Abstract][Full Text] [Related]
32. Comparison of second transplantation and donor lymphocyte infusion for donor mixed chimerism after allogeneic stem cell transplantation for nonmalignant diseases.
Umeda K; Adachi S; Tanaka S; Miki M; Okada K; Hashii Y; Inoue M; Cho Y; Koh K; Goto H; Kajiwara R; Hyakuna N; Kato K; Morio T; Yabe H;
Pediatr Blood Cancer; 2016 Dec; 63(12):2221-2229. PubMed ID: 27554591
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of Chimerism Dynamics after Allogeneic Hematopoietic Stem Cell Transplantation in Children with Nonmalignant Diseases.
Faraci M; Bagnasco F; Leoni M; Giardino S; Terranova P; Subissi L; Di Duca M; Di Martino D; Lanino E
Biol Blood Marrow Transplant; 2018 May; 24(5):1088-1093. PubMed ID: 29292059
[TBL] [Abstract][Full Text] [Related]
34. Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics.
Khouri IF; Albitar M; Saliba RM; Ippoliti C; Ma YC; Keating MJ; Champlin RE
Bone Marrow Transplant; 2004 Apr; 33(8):833-7. PubMed ID: 14755312
[TBL] [Abstract][Full Text] [Related]
35. Risk and promise: an 11-year, single-center retrospective study of severe acute GVHD in pediatric patients undergoing allogeneic HSCT for nonmalignant diseases.
Zaidman I; Even-Or E; Aharoni E; Averbuch D; Dinur-Schejter Y; NaserEddin A; Slae M; Shadur B; Stepensky P
Front Pediatr; 2023; 11():1194891. PubMed ID: 37303759
[TBL] [Abstract][Full Text] [Related]
36. Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease.
Gómez-Almaguer D; Ruiz-Argüelles GJ; del Carmen Tarín-Arzaga L; González-Llano O; Gutiérrez-Aguirre H; Cantú-Rodríguez O; Jaime-Pérez J; Carrasco-Yalán A; Giralt S
Biol Blood Marrow Transplant; 2008 Jan; 14(1):10-5. PubMed ID: 18158956
[TBL] [Abstract][Full Text] [Related]
37. An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis.
Marsh RA; Kim MO; Liu C; Bellman D; Hart L; Grimley M; Kumar A; Jodele S; Myers KC; Chandra S; Leemhuis T; Mehta PA; Bleesing JJ; Davies SM; Jordan MB; Filipovich AH
Biol Blood Marrow Transplant; 2013 Nov; 19(11):1625-31. PubMed ID: 24035782
[TBL] [Abstract][Full Text] [Related]
38. In vivo alemtuzumab enables haploidentical human leukocyte antigen-mismatched hematopoietic stem-cell transplantation without ex vivo graft manipulation.
Kanda Y; Oshima K; Asano-Mori Y; Kandabashi K; Nakagawa M; Sakata-Yanagimoto M; Izutsu K; Hangaishi A; Tsujino S; Ogawa S; Motokura T; Chiba S; Hirai H
Transplantation; 2005 May; 79(10):1351-7. PubMed ID: 15912103
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of donor lymphocyte infusion for treatment of mixed donor chimerism after a reduced-intensity preparative regimen for pediatric patients with nonmalignant diseases.
Haines HL; Bleesing JJ; Davies SM; Hornung L; Jordan MB; Marsh RA; Filipovich AH
Biol Blood Marrow Transplant; 2015 Feb; 21(2):288-92. PubMed ID: 25464116
[TBL] [Abstract][Full Text] [Related]
40. Peripheral Blood CD38 Bright CD8+ Effector Memory T Cells Predict Acute Graft-versus-Host Disease.
Khandelwal P; Lane A; Chaturvedi V; Owsley E; Davies SM; Marmer D; Filipovich AH; Jordan MB; Marsh RA
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1215-22. PubMed ID: 25881755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
